A trial has found that patients with an aggressive subtype of non-Hodgkin’s lymphoma are likely to benefit from an epigenetic drug, US researchers have reported.
The drug, azacitidine, is currently used in the US for myelodysplastic syndrome and s...
1 year ago
The atmosphere at this year’s Annual Scientific Meeting (ASM) was a particularly energetic mix of excitement and anticipation, alongside some trenchant discussion of the challenges facing the haematology workforce.
As nearly 1,600 delegates desce...
1 year ago